Medical imaging firm MolecuLight has received Health Canada approval for its diagnostic medical imaging device, MolecuLight i:X, for the treatment of chronic wounds.


The handheld fluorescence imaging device offers real-time visualization of bacteria in chronic wounds, and captures images just like a point-and-shoot digital camera.

MolecuLight founder, CSO and director Dr Ralph DaCosta said: "Canadian clinicians will now have a powerful new tool for more objective assessment of wound bacterial status and better antimicrobial treatment decision making."

MolecuLight i:X enables clinicians to effectively analyze the bacterial condition of chronic wounds with no patient contact or contrast agents.

The device allows clinicians to quickly and easily visualize and precisely target clinically important bacteria in and around chronic wounds in real-time at the bedside, helping them to start targeted and precise treatment plans.

The bacteriological information provided by the device will help clinicians in deciding whether the patients can be treated in a hospital, long-term treatment setting, at home, or in rural areas through telemedicine networks.

The clinical trials with MolecuLight i:X, including around 180 patients, showed that the device improved sample quality, healing rates, screen for high levels of bacteria and detect wound subsurface heavy bacte¬rial load subclinical local infection in patients.

MolecuLight CEO Craig Kennedy said: "This is a historic day for wound care, we will now be able to offer clinicians real-time diagnostic information about bacterial load at the bedside."

Based in Toronto, MolecuLight is involved in developing fluorescence image-guidance solutions to provide new information about bacterial wounds for better diagnostic and treatment decisions.

Image: MolecuLight i:X diagnostic medical imaging device. Photo: courtesy of PRNewswire/ MolecuLight Inc.